Using a sequencing test developed at Intermountain Healthcare, Navican Genomics will use precision medicine to identify individual mutations within cancer tumors. This ability to target mutations will help oncologists determine personalized cancer prevention and treatment options for patients.
Ingo Chakravarty, CEO and president of Navican Genomics, will lead a team in collaboration with physicians, pharmaceutical companies and other healthcare stakeholders to find treatments and clinical trials for patients.
More articles on health IT:
Kansas Health Information Network, Health Information Exchange Texas partner through eHealth Exchange
Survey: 17% of healthcare professionals report using mobile messages for protected health information
Instagram launches mental health feature
